Update information
February 2021: Section 1 of the guidance was updated because the commercial arrangement for trabectedin has changed. Section 2 was also updated because Immedica acquired the marketing and distribution rights to trabectedin in the UK from PharmaMar in 2019.
February 2014: Implementation section updated to clarify that trabectedin is recommended as an option for treating advanced soft tissue sarcoma. Additional minor maintenance update also carried out.
ISBN: 978-1-4731-4019-6